Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model

BACKGROUND: L-BLP25 antigen-specific cancer immunotherapeutic agent is currently in phase III clinical trials for non-small cell lung cancer. Using a novel human MUC1 transgenic (hMUC1.Tg) lung cancer mouse model, we evaluated effects of L-BLP25 combined with low-dose cyclophosphamide (CPA) pretreat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Wurz, Gregory T, Gutierrez, Audrey M, Greenberg, Brittany E, Vang, Daniel P, Griffey, Stephen M, Kao, Chiao-Jung, Wolf, Michael, DeGregorio, Michael W
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2013
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3605365/
https://ncbi.nlm.nih.gov/pubmed/23496860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-64
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki